Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma). [electronic resource]
Producer: 20191008Description: e473-e479 p. digitalISSN:- 1592-8721
- Aged
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Bortezomib -- administration & dosage
- Dexamethasone -- administration & dosage
- Disease-Free Survival
- Doxorubicin -- administration & dosage
- Female
- Humans
- Male
- Middle Aged
- Multiple Myeloma -- drug therapy
- Prospective Studies
- Survival Rate
- Vorinostat -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Letter; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.